#ESMO26 RAMPART：RCC 切除术后采用辅助 durvalumab 与主动监测相比，详细 PROs 显示了什么？
PRO 分析，n=218（Durvalumab: 87；主动监测: 131）
🚨 主要 QoL 终点在第 15 个月时显示两组之间无差异——但各领域层面的分析却揭示了不同的情况。
在第 16 周，durvalumab 治疗使以下指标恶化：
🔹 OHQL: –7.4
🔹 角色功能: –7.1
🔹 认知功能: –5.3
🔹 疲劳: +5.5
🔹 食欲丧失: +5.8
在第 15 个月：
🔹 认知功能仍较差: –7.1
🔹 食欲丧失: +7.4
🔹 呼吸困难: +7.5
🔹 便秘: +12.2
🔑 总体 QoL 终点可能会遗漏各个领域中具有临床意义的治疗效应——有些在治疗期间出现，有些持续存在，还有一些在后期才显现。
@urotoday
10 浏览 · 0 赞 · 0 转发 · 0 回复
Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
https://esmocongress.esmo.orgDurvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT
https://esmocongress.esmo.orgShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Rashid K. Sayyid · x.com